3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
7
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Neoplasms
1
Melanoma
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
10
fludarabine
7
pomalidomide
5
pembrolizumab
5
Dexamethasone
5
daratumumab
4
obinutuzumab
3
glofitamab
3
fludarabine phosphate
3
abemaciclib
3
Rituximab
3
Melphalan
3
Immunotherapy, Adoptive
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
pirtobrutinib
2
palbociclib
2
cemiplimab
2
blinatumomab
2
Temozolomide
2
Sirolimus
2
Oxaliplatin
2
Nivolumab
2
Mesna
2
Letrozole
2
Injections
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
osimertinib
×
30 days
×
Clear all
No trials found.